Wells Fargo analyst Derek Archila raised the firm’s price target on Apellis (APLS) to $29 from $26 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $29 from $26 at Wells Fargo
- Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
- Apellis price target lowered to $41 from $49 at Citi
- Apellis price target lowered to $20 from $30 at Mizuho
- Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion